Produced by ⁠Scholars in Medicine.com

Tune in to Derms on Drugs for a the most fun you can have while diving into the hottest dermatology topics! This week, we unpack cutting-edge insights from the latest literature to make you a sharper clinician. Explore adjuvant therapy for Stage 3A melanoma, the pitfalls of dermatomyositis misdiagnosis, and a surprising finding: is hydroxychloroquine outperforming NBUVB for vitiligo? Plus, discover new skin-gut-immune connections, tackle cancer immunotherapy-induced pemphigoid, and learn how to manage premenstrual rash flares in atopic dermatitis, contact dermatitis, and autoimmune progesterone dermatitis. Join our fun, banter-filled discussion to stay ahead in dermatology!
In This Episode:
Stage 3A Melanoma: Is adjuvant therapy worth it, and what’s the best option?
Dermatomyositis: Consequences of misdiagnosis and delayed diagnosis
Vitiligo: Could hydroxychloroquine be a game-changer over NBUVB?
Skin Inflammation: A key driver of food allergy
Pemphigoid: Insights into immunotherapy-induced cases
Premenstrual Rashes: Managing flares in atopic,


1. Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
2. Patterns and Clinical Implications of Misdiagnosis in Dermatomyositis
3. Effectiveness, Tolerability and Safety of Topical Clobetasol with Oral Hydroxychloroquine versus Topical Clobetasol with NBUVB Phototherapy in Unstable Vitiligo: Investigator Blind, Randomized Controlled Trial
4. Skin damage signals mediate allergic sensitization to spatially unlinked antigen
5. Epitope Spreading in Immune Checkpoint Inhibitor–Associated Bullous Pemphigoid
6. The impact of the menstrual cycle on exacerbations of atopic dermatitis: a systematic review
7. Nickel contact allergy and menstrual cycle
8. Autoimmune progesterone dermatitis: Update and insights

Should dermatologists offer Image Guided Superficial Radiation Therapy (IGSRT) in-office or refer radiation oncologists when radiation is appropriate? Join Derms on Drugs as we tackle this "burning" question with two expert radiation oncologists. While dermatologists are THE skin cancer experts, radiation therapy isn't our usual domain— so is IGSRT a game-changer for your practice or too far outside our realm? Explore clinical insights, practical considerations, and the latest evidence to guide your decision-making. Perfect for dermatologists, PAs, NPs, residents, medical students, and pharma professionals in dermatology seeking to stay ahead of the curve. Tune in to discover if IGSRT could light up your approach to patient care—or leave you glowing in the dark.


#Dermatology #SkinCancer #IGSRT #RadiationTherapy #DermEducation
1. Updated results of 3,050 non-melanoma skin cancer (NMSC) lesions in 1725 patients treated with high resolution dermal ultrasoundguided superficial radiotherapy, a multiinstitutional study

ScholarsInMedicine.com

2. The Role of Image-Guided Superficial Radiation Therapy in the Treatment of Nonmelanoma Skin Cancer
3. Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study

Buckle up for a whirlwind tour of the hottest dermatology literature. This week, we’ve got the deets on:

• Cutaneous squamous cell carcinoma: What predicts when it'll go rogue and metastasize? Spoiler: It’s not just bad vibes.
• Oral lichen planus: Turns out, its cancer risk is sneakier than a derm resident dodging clinic.
• Remibrutinib for CSU: The first oral game-changer for chronic spontaneous urticaria. Hives, meet your match!
• Psoriasis biologics: Which systemic treatments keep infections at bay? We’ve got the lowdown.
• Chemo’s conundrum: One bizarre trick to stop a cutaneous side effects

Hidradenitis suppurativa itch: Dermeleve’s here to make HS patients stop scratching and start living.
Join us for laughs, learning, and maybe a few gasps as we unpack the science that’s got the derm world buzzing. Perfect for dermatologists, PAs, NPs, pharma folks, and students who live for skin-deep insights. Subscribe, share, and let’s make dermatology lit! #DermatologyPodcast #DermLife

ScholarsinMedicine.com⁠

When a pathology report says 'melanoma,' the stakes are high. How confident are you in the diagnosis? Should you order gene expression profiling for better prognostic insights—or is it overrated?

Join the Derms on Drugs as we dig into the challenges of melanoma diagnosis and management. This week, we’re thrilled to feature Dr. Whitney High from the University of Colorado, the best-of-the-best dermatopathology expert, to share evidence-based answers with the Derms on Drugs flare our listeners expect.

Derms on Drugs is brought to you by ⁠⁠Scholars in Medicine.⁠

Resource links for this episode are available at ⁠Scholars in Medicine⁠.
1. Society of Surgical Oncology Consensus Statement: Assessing the Evidence for and Utility of Gene Expression Profiling of Primary Cutaneous Melanoma

2. 31-GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort

3. CLO25-055: Metastasis-Free Survival Prediction With the 40-Gene Expression Profile Test in Patients With Cutaneous Squamous Cell Carcinoma Risk Stratified According to the National Comprehensive Cancer Network Guidelines

4. CGE25-104: The 31-GEP Identifies Patients With Early-Stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-Specific and Overall Mortality

Does Dupixent raise the risk of cutaneous T-cell lymphoma (CTCL) in atopic dermatitis patients? It’s the burning question gripping dermatology—and we’ve got answers.

Join the Derms on Drugs team as we unpack the latest with Dr. Shamir Geller, who runs a CTCL clinic at Memorial Sloan Kettering and published the first data that truly helps us understand if there is a Dupixent - CTCL link.

Plus, we dive into CTCL survival stats and must-know updates for practicing dermatologists. Essential listening for anyone who is taking care of dermatology patients.

Derms on Drugs is brought to you by Scholars in Medicine.

Guest: Shamir Geller, MD

Associate Attending Physician Dermatology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY

Associate Professor of Clinical Dermatology, Department of Dermatology, Weill Cornell Medicine, New York, NY

I’m a dermatologist interested mainly in cutaneous lymphoma. During my cutaneous oncology fellowship at Memorial Sloan Kettering Cancer Center (MSK) between the years 2016-2019, I became a cutaneous lymphoma enthusiast, working at MSK multi-disciplinary cutaneous lymphoma clinic. Under the mentorship of expert faculty in dermatology, oncology, and pathology, I was able to master the art of integrating clinical findings, histopathologic features, clinical laboratory data, and molecular characteristics to reach to the diagnosis and most suitable treatment. After my fellowship I was appointed as an attending physician in the cutaneous lymphoma clinic at Tel Aviv Sourasky Medical Center in Israel and provided care for patients with cutaneous lymphomas while continuing to pursue research in the field.

In early 2023 I returned to New York to the cutaneous lymphoma clinic at MSKCC as an associate attending. Other than clinical work and research, I dedicate a large portion of my time and effort to teaching and mentoring students, residents, fellows and visiting physicians. My research projects have been published in the leading dermatology, hematology and oncology journals and I’ve been invited and chosen to present my works in numerous regional, national and international conferences (ASH, USCLC, WCCL, EORTC, SID, AAD, EADV and others). I’m frequently asked to peer-review manuscripts on lymphomas of the skin and I also assist the cutaneous lymphoma foundation (CLF) with the preparation of patients’ education materials and lectures.

Resource links for this episode available at ⁠Scholars in Medicine⁠.

1. Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy
2. Overall and Cause-Specific Mortality Among Patients With Cutaneous T-Cell Lymphoma in the United States
3. Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: A retrospective cohort study from a single tertiary cancer center
   

Late-breaking abstracts from the AAD Meeting offer a sneak peek into dermatology’s future—and we’ve done the heavy lifting for you. Derms on Drugs uncovers the hottest data that will dominate the top journals and meetings in 2025: the cutting-edge for psoriasis, new Tyk2 inhibitors, new treatment for cutaneous lupus, dupilumab’s possible role in bullous pemphigoid, patient-led patch testing innovations, plus fresh approaches to skin cancer and alopecia areata. Tune in to stay ahead of the curve!

This podcast is brought to you by Scholars in Medicine.

New Articles on causes and treatments for AKs, Melasma, Atopic Derm, Acne, Grover's and Contact Derm. But you can't always believe what you read in a journal, and even when you can it doesn't mean it's going to help your patients. So, sit back, relax and join the Derms on Drugs to separate fact from fiction.

• A systemic option for patients with tons of actinic keratoses all over their body? If it sounds too good to be true it probably is, right?
• Botox for melasma. Can you see the difference? Can the Derms on Drugs?
• New "Real World" data says Dupixent doesn't help 85% of patients. Are the authors living in the "Real World"?
• Hormonal IUDs cause acne - Fact, fiction or the jury is still out?
• Grover's Disease (aka transient acantholytic dermatosis) isn't always so transient. Do we finally have a breakthrough?
• Positive Patch Tests in Kids - do they actually get better or is it just sending us down a rabbit hole?

Derms on Drugs is brought to you by Scholars in Medicine.

Resource links for this episode available at Scholars in Medicine.

1. Immune Checkpoint Inhibitors in Field Cancerization and Keratinocyte Cancer Prevention
2. Intradermal Botulinum Toxin A for Melasma: A Randomized Split-Face Study Trial and In Vitro Study of Its Antimelanogenic Effect⁠
3. Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry
4. Frequency of androgenic cutaneous adverse events associated with levonorgestrel intrauterine devices: An analysis of the Food and Drug Administration Adverse Event Reporting System database
5. Efficacy of Dupilumab for Treatment-Resistant Grover's Disease: A Retrospective Study⁠
6. Association of Somatic ATP2A2 Damaging Variants With Grover Disease ⁠
7. Discrepancies in patch testing timing and outcomes: A retrospective analysis of the Pediatric Allergic Contact Dermatitis Registry

The Derms on Drugs enlist the Sultan of Scratching, Dan Kaplan from the University of Pittsburgh, to answer the age- old question - should you scratch an itch or not?

Believe it or not, some of the most cutting-edge science on the planet is focusing on this question (you think they'd have better stuff to work on, but who are we to judge). The answer(s) are going to surprise you - turns out scratching does a lot more than just get bugs off our skin (although that part is important too).

Derms on Drugs is brought to you by Scholars in Medicine.

Guest: Daniel H. Kaplan, MD, PhD

Daniel H. Kaplan, MD, PhD is a Professor within the Department of Dermatology and Immunology, University of Pittsburgh. His research is dedicated to understanding the mechanisms that underlie skin immunity and the interplay of different immune cells types that reside in the skin. As a graduate student at Washington University, St Louis he participated in the re-invigoration of the concept of tumor immunosurveillance by observing an increased frequency of skin tumors in immunodeficient mice. During his post-doc at Yale University, he developed a number of mouse lines with a selective deficiency of Langerhans cells (LC) and showed that these cells have the unexpected capacity to suppress tissue immune. As an Assistant and later Associate professor at the University of Minnesota, he found that LC and dermal dendritic cells have unique functions in the development of anti-pathogen responses. In 2015 he moved to the University of Pittsburgh. His laboratory is currently focused on understanding how intracellular communication mechanisms between immune cells and non-hematopoietic cells in the skin with a particular emphasis on sensory afferents modulate cutaneous immunity and skin disease.

Resource links for this episode are available at ⁠Scholars in Medicine⁠.

1. Brain's reward circuits mediate itch relief. a functional MRI study of active scratching
2. Epidermal Mechanical Scratching-Induced ROS Exacerbates the Itch-Scratch Cycle via TRPA1 Activation on Mast Cells in Atopic Dermatitis
3. Scratching promotes allergic inflammation and host defense via neurogenic mast cell activation
4. Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch
5. Mast-Cell-Derived TNF Amplifies CD8(+) Dendritic Cell Functionality and CD8(+) T Cell Priming
6. Mast Cells Initiate Type 2 Inflammation through Tryptase Released by MRGPRX2/MRGPRB2 Activation in Atopic Dermatitis